Abstract:Introduction: During HIV infection the severe depletion of intestinal CD4 T-cells is associated with microbial translocation, systemic immune activation, and disease progression. This study examined intestinal and peripheral CD4 T-cell subsets reconstitution under combined antiretroviral therapy (cART), and systemic immune activation markers. Methods: This longitudinal single-arm pilot study evaluates CD4 T cells, including Th1 and Th17, in gut and blood and soluble markers for inflammation in HIV-infected individuals before (M0) and after eight (M8) months of cART. From January 2010 to December 2011, 10 HIV-1 naı̈ve patients were screened and 9 enrolled. Blood and gut CD4 T-cells subsets and cellular immune activation were determined by flow-cytometry and plasma soluble CD14 by ELISA. CD4 Th17 cells were detected in gut biopsies by immunohistochemistry. Microbial translocation was measured by limulus-amebocyte-lysate assay to detect bacterial lipopolysaccharide (LPS) and PCR Real Time to detect plasma bacterial 16S rDNA. Results: Eight months of cART increased intestinal CD4 and Th17 cells and reduced levels of T-cell activation and proliferation. The magnitude of intestinal CD4 T-cell reconstitution correlated with the reduction of plasma LPS. Importantly, the magnitude of Th17 cells reconstitution correlated directly with blood CD4 T-cell recovery. Conclusion: Short-term antiretroviral therapy resulted in a significant increase in the levels of total and Th17 CD4 T-cells in the gut mucosa and in decline of T-cell activation. The observation that pre-treatment levels of CD4 and of CD8 T-cell activation are predictors of the magnitude of Th17 cell reconstitution following cART provides further rationale for an early initiation of cART in HIV-infected individuals. Trial Registration: ClinicalTrials.gov NCT02097381 Citation: d’Ettorre G, Baroncelli S, Micci L, Ceccarelli G, Andreotti M, et al. (2014) Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE 9(10): e109791. doi:10.1371/journal. pone.0109791 Editor: Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Italy Received April 13, 2014; Accepted September 4, 2014; Published October 23, 2014 Copyright: 2014 d’Ettorre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper, anyway the complete database is freely available from the archive of Department of Public Health and Infectious Diseases of University of Rome ‘‘Sapienza’’ (Italy). This is because the Italian law on privacy does not allow the online publication of complete databases with sensitive data. All data are available upon request contacting Dr. Gabriella d’Ettorre MD PhD. Department of Public Health and Infectious Diseases. Viale del Policlinico 155 (00161) Rome (Italy). Tel 0039-06-49970313, fax 0039-06-49972625, email gabriella.dettorre@uniroma1.it. Funding: This work was supported by ISS ‘‘Programma Italia Usa’’ (to AM) and by National Institutes of Health grant R01-AI-084836 (to MP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * Email: gabriella.dettorre@uniroma1.it PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109791

Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis

Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment

Integrin Α4β7 is an Immunological Marker for HIV Preference in Activated Peripheral and Cervical CD4+ T Cells (VIR8P.1066)

Monitoring α4β7 integrin expression on circulating CD4+ T cells as a surrogate marker for tracking intestinal CD4+ T-cell loss in SIV infection

OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis

Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration

P650 Integrin expression patterns of patients with IBD treated with vedolizumab

Brief Report: Inflammatory Colonic Innate Lymphoid Cells Are Increased During Untreated HIV-1 Infection and Associated With Markers of Gut Dysbiosis and Mucosal Immune Activation

Reconstitution of Intestinal CD 4 and Th 17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects : Implication for Residual Immune Activation from the Results of a Clinical Trial

P016 Reduction of mucosal (active) eosinophils, B cells and T cells after vedolizumab therapy in patients with ulcerative colitis

Characterization of CD31 expression in CD4+ and CD8+T cell subpopulations in chronic untreated HIV infection

OP39 Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signaling

Expression of α4β7 integrin on memory CD8 + T cells at the presentation of acute intestinal GVHD

Novel Immunological Markers of Intestinal Impairment Indicative of HIV-1 Status and/or Subclinical Atherosclerosis

Gastrointestinal germinal center B cell depletion and reduction in IgA + plasma cells in HIV-1 infection

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Antiretroviral Therapy Dampens Mucosal CD4+ T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1

Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis